Merck (MRK) reported Q4 FY 2017 earnings of $0.98 per share (versus $0.89 in Q4 FY 2016), beating analysts' consensus estimate of $0.94.
The company's quarterly revenues amounted to $10.433 bln (+3.1% y/y), generally in-line with analysts' consensus estimate of $10.485 bln.
The company also issued guidance for FY 2018, projecting EPS of $4.08-4.23 (versus analysts' consensus estimate of $4.11) and revenues of $41.2-42.7 bln (versus analysts' consensus estimate of $41.1 bln).
MRK rose to $60.00 (+0.23%) in pre-market trading.